Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
As the respective macrocycles were selected as peptidemRNA fusions via a carboxy-terminal (GS) 3 -linker, each peptides C-terminus appeared likely to tolerate not only FLAG modification but also binding to an anti-FLAG monoclonal antibody (mAb) without compromising the structure of the active macrocyclic region
Trajkovski, M
Statistical analysis The planned sample size of 495 participants was estimated to provide over 80% statistical power to detect a difference between any active treatment group and placebo with respect to the primary endpoint using a two-sided t -test with significance level of 0.05
Men who maintain protocols for twelve months and beyond often achieve results exceeding clinical trial averages
US$ 20.16
US$ 20.42
US$ 26.50
US$ 20.45
US$ 20.57
US$ 29.31
US$ 20.54
